Basel Medical Net Income Over Time
| BMGL Stock | 0.63 0.02 3.28% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Basel Medical Performance and Basel Medical Correlation. Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Basel Medical. Projected growth potential of Basel fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Basel Medical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (0.51) | Revenue Per Share | Quarterly Revenue Growth 0.322 | Return On Assets | Return On Equity |
Investors evaluate Basel Medical Group using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Basel Medical's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Basel Medical's market price to deviate significantly from intrinsic value.
It's important to distinguish between Basel Medical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Basel Medical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Basel Medical's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Basel Medical Group and related stocks such as P3 Health Partners, Vicarious Surgical, and Longduoduo Limited Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PIII | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (43.8 M) | (42 M) | (31.4 M) | (270.1 M) | (270.1 M) | (57.8 M) | (135.8 M) | (122.3 M) | (128.4 M) |
| RBOT | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (9.3 M) | (12.9 M) | (35.2 M) | 5.2 M | (71.1 M) | (63.2 M) | (56.9 M) | (54.1 M) |
| PRPO | (9.8 M) | (9.8 M) | (8.3 M) | (16 M) | (13.9 M) | (33 M) | (7.6 M) | (20.7 M) | (15.7 M) | (13.2 M) | (10.6 M) | (8.6 M) | (12.2 M) | (5.9 M) | (4.3 M) | (4.9 M) | (5.2 M) |
| IBIO | (1.7 M) | (5.7 M) | (6.2 M) | (3.7 M) | (6.6 M) | (9.8 M) | (14.5 M) | (16.1 M) | (17.6 M) | (16.4 M) | (23.2 M) | (50.4 M) | (29.3 M) | (24.9 M) | (18.4 M) | (16.5 M) | (17.4 M) |
| NTRB | (400) | (400) | (400) | (400) | (400) | (400) | (151.3 K) | (2.7 M) | (3.3 M) | (2.8 M) | (3.2 M) | (8.4 M) | (4.8 M) | (5.5 M) | (10.5 M) | (9.4 M) | (9 M) |
| ITRM | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (13.5 M) | (29.4 M) | (77.1 M) | (103.1 M) | (52 M) | (91.6 M) | (44.4 M) | (38.4 M) | (24.8 M) | (28.5 M) | (29.9 M) |
| INTS | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (5.2 M) | (6 M) | (7.9 M) | (7.6 M) | (10.5 M) | (16.3 M) | (14.6 M) | (13.9 M) |
| TLPH | (9.6 M) | (20.1 M) | (33.4 M) | (23.4 M) | (33.4 M) | (24.4 M) | (43.2 M) | (51.5 M) | (47.1 M) | (53.2 M) | (40.4 M) | (35.1 M) | 42.5 M | (18.4 M) | (13 M) | (15 M) | (15.7 M) |
| MODD | (30 K) | (17.5 K) | (20.8 K) | (22.8 K) | (31 K) | (31.1 K) | (106.6 K) | (106.6 K) | (2.5 M) | (5.3 M) | (7.4 M) | (18.6 M) | (13.9 M) | (17.5 M) | (18.8 M) | (16.9 M) | (16.1 M) |
Basel Medical Group and related stocks such as P3 Health Partners, Vicarious Surgical, and Longduoduo Limited Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Basel Medical Group financial statement analysis. It represents the amount of money remaining after all of Basel Medical Group operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Basel Medical Group | BMGL |
| Classification | Drugs |
| Business Address | Gleneagles Medical Centre, |
| Exchange | NASDAQ Exchange |
null 0.63
Check out Basel Medical Performance and Basel Medical Correlation. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Basel Medical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.